➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKesson
McKinsey
AstraZeneca
Johnson and Johnson

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,028,937

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,028,937
Title:Anti-viral compounds
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Inventor(s): Bellizzi; Mary E. (Missoula, MT), Betebenner; David A. (Grayslake, IL), Califano; Jean-Christophe C. (Whitefish Bay, WI), Carroll; William A. (Evanston, IL), Caspi; Daniel D. (Evanston, IL), DeGoey; David A. (Salem, WI), Donner; Pamela L. (Mundelein, IL), Flentge; Charles A. (Pittsburgh, PA), Gao; Yi (Vernon Hills, IL), Hutchins; Charles W. (Green Oaks, IL), Hutchinson; Douglas K. (Newton, CT), Jinkerson; Tammie K. (Pleasant Prairie, WI), Kati; Warren M. (Gurnee, IL), Keddy; Ryan G. (Beach Park, CA), Krueger; Allan C. (Gurnee, IL), Li; Wenke (Gurnee, CN), Liu; Dachun (Vernon Hills, CN), Maring; Clarence J. (Palatine, IL), Matulenko; Mark A. (Libertyville, IL), Motter; Christopher E. (Oak Creek, WI), Nelson; Lissa T. (Highland Park, IL), Patel; Sachin V. (Round Lake, IL), Pratt; John K. (Kenosha, WI), Randolph; John T. (Libertyville, IL), Rockway; Todd W. (Grayslake, IL), Sarris; Kathy (Mundelein, IL), Tufano; Michael D. (Chicago, IL), Wagaw; Seble H. (Lake Bluff, IL), Wagner; Rolf (Antioch, IL), Woller; Kevin R. (Antioch, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:15/434,789
Patent Claims: 1. A method of treating HCV infection, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, and an HCV protease inhibitor, to an HCV patient in need thereof, ##STR00967## wherein: X is ##STR00968## wherein X.sub.3 is N which is directly linked to -L.sub.3-D, and X is optionally substituted with one or more R.sub.A; L.sub.1, L.sub.2 and L.sub.3 are bond; A is ##STR00969## and is optionally substituted with one or more R.sub.A; B is ##STR00970## and is optionally substituted with one or more R.sub.A; D is C.sub.3-C.sub.12carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more R.sub.A; Y is -L.sub.S-C(R.sub.1R.sub.2)N(R.sub.5)--C(O)-L.sub.Y'-N(R.sub.B)C(O)O--R.su- b.D, -L.sub.S-C(R.sub.1R.sub.2)N(R.sub.5)--C(O)-L.sub.Y'-N(R.sub.B)C(O)--R- .sub.D; Z is -L.sub.S-C(R.sub.8R.sub.9)N(R.sub.12)--C(O)-L.sub.Y'-N(R.sub.B)C(O)O--R.s- ub.D or -L.sub.S-C(R.sub.8R.sub.9)N(R.sub.12)--C(O)-L.sub.Y'-N(R.sub.B)C(O- )--R.sub.D; L.sub.Y' is each independently C.sub.1-C.sub.6alkylene which is optionally substituted with one or more R.sub.L; R.sub.1 is R.sub.C; R.sub.2 and R.sub.5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle which is optionally substituted with one or more R.sub.A; R.sub.8 is R.sub.C; R.sub.9 and R.sub.12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6- to 12-membered bicycle which is optionally substituted with one or more R.sub.A; R.sub.D is each independently selected at each occurrence from hydrogen or R.sub.A; R.sub.A is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L.sub.S-R.sub.E; R.sub.B is independently selected at each occurrence from hydrogen; or C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl or C.sub.2-C.sub.6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R.sub.B is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6haloalkenyl or C.sub.2-C.sub.6haloalkynyl; R.sub.C is independently selected at each occurrence from hydrogen, halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl or C.sub.2-C.sub.6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R.sub.C is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6haloalkenyl or C.sub.2-C.sub.6haloalkynyl; R.sub.E is independently selected at each occurrence from --O--R.sub.S, --S--R.sub.S, --C(O)R.sub.S, --OC(O)R.sub.S, --C(O)OR.sub.S, --N(R.sub.SR.sub.S'), --S(O)R.sub.S, --SO.sub.2R.sub.S, --C(O)N(R.sub.SR.sub.S'), --N(R.sub.S)C(O)R.sub.S', --N(R.sub.S)C(O)N(R.sub.S'R.sub.S''), --N(R.sub.S)SO.sub.2R.sub.S', --SO.sub.2N(R.sub.SR.sub.S'), --N(R.sub.S)SO.sub.2N(R.sub.S'R.sub.S''), --N(R.sub.S)S(O)N(R.sub.S'R.sub.S''), --OS(O)--R.sub.S, --OS(O).sub.2--R.sub.S, --S(O).sub.2OR.sub.S, --S(O)OR.sub.S, --OC(O)OR.sub.S, --N(R.sub.S)C(O)OR.sub.S', --OC(O)N(R.sub.SR.sub.S'), --N(R.sub.S)S(O)--R.sub.S', --S(O)N(R.sub.SR.sub.S') or --C(O)N(R.sub.S)C(O)--R.sub.S'; or C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl or C.sub.2-C.sub.6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C.sub.3-C.sub.6carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6haloalkenyl or C.sub.2-C.sub.6haloalkynyl; R.sub.L is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, --O--R.sub.S, --S--R.sub.S, --C(O)R.sub.S, --OC(O)R.sub.S, --C(O)OR.sub.S, --N(R.sub.SR.sub.S'), --S(O)R.sub.S, --SO.sub.2R.sub.S, --C(O)N(R.sub.SR.sub.S') or --N(R.sub.S)C(O)R.sub.S'; or C.sub.3-C.sub.6carbocycle 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6haloalkenyl or C.sub.2-C.sub.6haloalkynyl; L.sub.S is independently selected at each occurrence from bond; or C.sub.1-C.sub.6alkylene, C.sub.2-C.sub.6alkenylene or C.sub.2-C.sub.6alkynylene, each of which is independently optionally substituted at each occurrence with one or more R.sub.L; and R.sub.S, R.sub.S' and R.sub.S'' are each independently selected at each occurrence from hydrogen; C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl or C.sub.2-C.sub.6alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R.sub.S, R.sub.S' or R.sub.S' is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C.sub.1-C.sub.6alkyl, C.sub.2-C.sub.6alkenyl, C.sub.2-C.sub.6alkynyl, C.sub.1-C.sub.6haloalkyl, C.sub.2-C.sub.6haloalkenyl or C.sub.2-C.sub.6haloalkynyl.

2. The method of claim 1, wherein: R.sub.2 and R.sub.5, taken together with the atoms to which they are attached, form ##STR00971## which is optionally substituted with one or more R.sub.A R.sub.9 and R.sub.12, taken together with the atoms to which they are attached, form ##STR00972## which is optionally substituted with one or more R.sub.A.

3. A method of treating HCV infection, comprising administering an effective amount of methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piper- idin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-th- reonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1H-- benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate or a pharmaceutically acceptable salt thereof, and an HCV protease inhibitor, to an HCV patient in need thereof.

4. A method of treating HCV infection, comprising: making a pharmaceutical composition comprising methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piper- idin-1-yl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-th- reonyl]pyrrolidin-2-yl}-1H-benzimidazol-5-yl)pyrrolidin-2-yl]-6-fluoro-1H-- benzimidazol-2-yl}pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl}carbamate or a pharmaceutically acceptable salt thereof, and an HCV protease inhibitor; and administering said pharmaceutical composition to an HCV patient in need thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
Merck
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.